NO331271B1 - Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling - Google Patents

Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling

Info

Publication number
NO331271B1
NO331271B1 NO20033673A NO20033673A NO331271B1 NO 331271 B1 NO331271 B1 NO 331271B1 NO 20033673 A NO20033673 A NO 20033673A NO 20033673 A NO20033673 A NO 20033673A NO 331271 B1 NO331271 B1 NO 331271B1
Authority
NO
Norway
Prior art keywords
protein
interest
supernatant
secretion
plasmid
Prior art date
Application number
NO20033673A
Other languages
English (en)
Norwegian (no)
Other versions
NO20033673D0 (no
NO20033673L (no
Inventor
Paul Habermann
Johann Ertl
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of NO20033673D0 publication Critical patent/NO20033673D0/no
Publication of NO20033673L publication Critical patent/NO20033673L/no
Publication of NO331271B1 publication Critical patent/NO331271B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/62Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/815Protease inhibitors from leeches, e.g. hirudin, eglin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • C12N15/625DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20033673A 2001-02-20 2003-08-19 Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling NO331271B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10108212A DE10108212A1 (de) 2001-02-20 2001-02-20 Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände
PCT/EP2002/001307 WO2002068660A1 (en) 2001-02-20 2002-02-08 Fusion protein for the secretion of a protein of interest into the supernatant of the bacterial culture

Publications (3)

Publication Number Publication Date
NO20033673D0 NO20033673D0 (no) 2003-08-19
NO20033673L NO20033673L (no) 2003-10-17
NO331271B1 true NO331271B1 (no) 2011-11-14

Family

ID=7674913

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20033673A NO331271B1 (no) 2001-02-20 2003-08-19 Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling

Country Status (19)

Country Link
EP (1) EP1364029B1 (de)
JP (1) JP4243104B2 (de)
KR (1) KR100858009B1 (de)
CN (1) CN100500853C (de)
AT (1) ATE314480T1 (de)
AU (1) AU2002231784B2 (de)
BR (1) BRPI0207394B8 (de)
CA (1) CA2438886C (de)
DE (2) DE10108212A1 (de)
DK (1) DK1364029T3 (de)
ES (1) ES2254658T3 (de)
HK (1) HK1065335A1 (de)
IL (1) IL157414A0 (de)
MX (1) MXPA03007114A (de)
NO (1) NO331271B1 (de)
NZ (1) NZ527643A (de)
PE (1) PE20020876A1 (de)
WO (1) WO2002068660A1 (de)
ZA (1) ZA200305869B (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
EP2327718B1 (de) 2003-11-21 2016-03-23 Pfenex, Inc. Verbessertes Expressionssystem mit SEC-System-Sekretion
KR20120076377A (ko) 2004-01-16 2012-07-09 다우 글로벌 테크놀로지스 엘엘씨 슈도모나스 플루오레센스에서의 포유류 단백질의 발현
CN101031655A (zh) 2004-07-26 2007-09-05 陶氏环球技术公司 通过株工程改进蛋白表达的方法
DE102006031962A1 (de) 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
DE102006031955A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
DE102006050332A1 (de) 2006-10-25 2008-04-30 Wacker Chemie Ag DNS-Konstrukt und Verfahren zur fermentativen Herstellung von Fusionsproteinen
KR101491867B1 (ko) 2007-01-31 2015-02-10 피페넥스 인크. 증가된 발현을 위한 박테리아 리더 서열
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CA2711749A1 (en) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Novel insulin derivatives having an extremely delayed time-action profile
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2344524B1 (de) 2008-10-02 2019-12-04 Unitargeting Research As Kit zur optimierung der proteinsynthese/sezernierung
RS56632B1 (sr) 2008-10-17 2018-03-30 Sanofi Aventis Deutschland Kombinacija insulina i glp-1-agonista
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
AU2010317995B2 (en) 2009-11-13 2014-04-17 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin, and methionine
JP6199186B2 (ja) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 2型糖尿病の治療用の医薬の製造のためのave0010の使用
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
JP6367115B2 (ja) 2011-08-29 2018-08-01 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 2型糖尿病患者の血糖コントロールに使用する組合せ医薬
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
KR20160029731A (ko) 2013-03-12 2016-03-15 더 제너럴 하스피탈 코포레이션 변형된 뮐러관 억제 물질(mis) 단백질 및 질환 치료를 위한 그 용도
EP3079712B1 (de) 2013-12-11 2022-02-02 The General Hospital Corporation Verwendung von anti-müller-hormon (amh)-proteine zur kontrazeption und ovariellen reservekonservierung
MX2017007699A (es) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Formulacion de proporcion fija de insulina glargina/lixisenatida.
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第2型糖尿病病患之治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341414C (fr) * 1984-03-27 2002-12-31 Paul Tolstoshev Vecteurs d'expression de l'hirudine, cellules transformees et procede de preparation de l'hirudine
GB8927722D0 (en) * 1989-12-07 1990-02-07 British Bio Technology Proteins and nucleic acids
CA2255396A1 (en) * 1990-11-08 1992-05-09 Nippon Mining Company Limited Hirudin analog, method of manufacturing thereof and anti-coagulant composition, and secretion vector, transformed microorganisms containing said vector and manufacturing method ofproducts which is produced from said microorganism
WO1995009125A1 (en) * 1992-09-28 1995-04-06 Pehr Harold T Kicker latch for container closures
DE10033195A1 (de) * 2000-07-07 2002-03-21 Aventis Pharma Gmbh Bifunktionale Fusionsproteine aus Hirudin und TAP

Also Published As

Publication number Publication date
NZ527643A (en) 2005-07-29
MXPA03007114A (es) 2003-11-18
CN1529757A (zh) 2004-09-15
JP2004518444A (ja) 2004-06-24
ATE314480T1 (de) 2006-01-15
DE10108212A1 (de) 2002-08-22
ES2254658T3 (es) 2006-06-16
PE20020876A1 (es) 2002-11-05
DE60208343T2 (de) 2006-06-22
AU2002231784B2 (en) 2006-10-26
KR20030074842A (ko) 2003-09-19
JP4243104B2 (ja) 2009-03-25
EP1364029B1 (de) 2005-12-28
DK1364029T3 (da) 2006-05-08
NO20033673D0 (no) 2003-08-19
KR100858009B1 (ko) 2008-09-11
CA2438886A1 (en) 2002-09-06
IL157414A0 (en) 2004-03-28
DE60208343D1 (de) 2006-02-02
BRPI0207394B8 (pt) 2021-05-25
CA2438886C (en) 2013-07-23
WO2002068660A1 (en) 2002-09-06
BR0207394A (pt) 2004-02-10
CN100500853C (zh) 2009-06-17
ZA200305869B (en) 2004-06-25
NO20033673L (no) 2003-10-17
HK1065335A1 (en) 2005-02-18
BRPI0207394B1 (pt) 2015-06-16
EP1364029A1 (de) 2003-11-26

Similar Documents

Publication Publication Date Title
NO331271B1 (no) Fusjonsprotein for sekresjon av et protein av interesse til supernatanten til en bakteriekultur, fremgangsmate, plasmid og vertscelle for fremstilling
NZ521396A (en) Fusion proteins comprising two or more Neisseria polypeptides
EP1470236A4 (de) Verfahren und zusammensetzungen für die proteinexpression und reinigung
WO2005003313A8 (en) Methods and compositions for enhanced protein expression and purification
WO2005071088A3 (en) Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
MX2007006946A (es) Aislado de proteina de soya y proceso para su manufactura.
HUP9800730A2 (hu) Expressziós rendszer heterológ antigének fúziós proteinként történő expresszáltatására
SG162834A1 (en) Refolding of recombinant proteins
DE60333201D1 (de) Verfahren zur herstellung von proteinen
AU2002360331A1 (en) Egviii endoglucanase and nucleic acids encoding the same
ATE457352T1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
NO20053033D0 (no) Anvendelse av caspase enzymer for modning av konstruerte rekombinante polypeptidfusjoner.
WO2004053137A3 (en) Method for protein production
GB0208041D0 (en) Method of culturing animal cells
AU2003252111A1 (en) Fluorescent proteins, nucleic acids encoding them and methods for making and using them
HK1098673A1 (zh) 重組編碼融合蛋白的核酸分子,該融合蛋白包括抗原和細菌分泌的信號多肽,表達框架,和細菌,及其使用方法
EP1481061A4 (de) Gegen denaturierungsmittel stabile und/oder proteaseresistente, chaperonähnliche oligomere proteine, diese kodierende polynukleotide sowie ihre verwendungen
HUP0203221A2 (hu) A lignin bioszintézisében résztvevő enzimeket kódoló gének és alkalmazásuk
AU2003298523A1 (en) Methods for efficient production of mammalian recombinant proteins
DK0941241T3 (da) Bordetella-stamme, som udtrykker hybridet FHA
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU2001240540A1 (en) Method for the manufacture of recombinant trypsin
DK1002056T3 (da) ppGpp-syntease og ekspressionssystem til forbedret fremstilling af protein af interesse
ATE495245T1 (de) Verbesserte proteinexpression in bacillus subtilis
AU2002348573A1 (en) Method of increasing expression of heterologous proteins in plants

Legal Events

Date Code Title Description
MK1K Patent expired